25Nov/13

Cardiac Biomarker ST2 Proves Valuable In Helping Risk Assess Heart Failure … – PharmiWeb.com (press release)

Cardiac Biomarker ST2 Proves Valuable In Helping Risk Assess Heart Failure
PharmiWeb.com (press release)
Given that over 80% of heart failure patients are 65 years of age or older1 it’s no wonder then that according to the American Heart Association the number of Americans with heart failure is expected to jump from just over 5 million today to 8 million

and more »

25Nov/13

Creating synthetic antibodies – R & D Magazine


R & D Magazine

Creating synthetic antibodies
R & D Magazine
To create these “synthetic antibodies,” the researchers used carbon nanotubes—hollow, nanometer-thick cylinders made of carbon that naturally fluoresce when exposed to laser light. In the past, researchers have exploited this phenomenon to create
Team Creates ‘Synthetic AntibodiesBioscience Technology
Synthetic antibodies work in new sensortce today

all 8 news articles »

25Nov/13

UPA Chairperson Felicitates India's First Successful Liver Transplant … – PR Newswire India (press release)

UPA Chairperson Felicitates India’s First Successful Liver Transplant
PR Newswire India (press release)
UPA Chairperson and Congress Party President, Smt. Sonia Gandhi today felicitated India’s first successful liver transplant recipient, Sanjay Kandasamy from Kancheepuram, Tamil Nadu who had undergone a liver transplant in November 1998 at Apollo 

and more »

25Nov/13

US group opposes Gilead's patenting of hepatitis C drug in India – domain-B


Hindu Business Line

US group opposes Gilead’s patenting of hepatitis C drug in India
domain-B
US drug-maker Gilead Sciences’ patent application on hepatitis C drug sofosbuvir in India is facing opposition from a US legal group I-MAK (Initiative for Medicines, Access & Knowledge) on the ground that it is old known compound and has nothing new to
US group seeks to block Gilead drug patent in IndiaEconomic Times
US group against Gilead’s patent request in India for hepatitis C drugTopNews United States
Indian health activists move to prevent Gilead’s drug patentFinancial Times

all 94 news articles »

25Nov/13

Support from InvestNI Allows Fusion Antibodies to Develop New Technologies – HispanicBusiness.com

Support from InvestNI Allows Fusion Antibodies to Develop New Technologies
HispanicBusiness.com
Fusion Antibodies, a spin out from Queen’s University, Belfast , is currently employing 10 people in its labs at Springbank Industrial Estate , near Lisburn . It is using Invest NI R&D support to develop technology services to further the work of

and more »